CLOMIPRAMINE HYDROCHLORIDE (clomipramine hydrochloride capsules) by Lupin Ltd. is clinical pharmacology pharmacodynamics clomipramine (cmi) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. Approved for obsessions, compulsions in patients with obsessive-compulsive disorder (ocd). First approved in 2018.
Drug data last refreshed 7h ago
CLINICAL PHARMACOLOGY Pharmacodynamics Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought…
Worked on CLOMIPRAMINE HYDROCHLORIDE at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions